|Title: "Molecular histology with imaging mass spectrometry"
Date & Time: Jul 11, 2012 12:00 PM - 1:00 PM
Location: CHS 23-105 (2nd Floor Lecture Hall)
UCLA Department of Pathology & Laboratory Medicine presents:
Shannon Cornett, Ph.D.
Applications Development Manager, Bruker Daltonics
Molecular histology with imaging mass spectrometry
Wednesday, July 11, 2012
12:00 – 1:00 PM
CHS 23-105 (2nd Floor Lecture Hall)
For additional information please contact:
Justin Perry, email@example.com
Imaging Mass spectrometry (IMS) is a unique analysis tool that can detect and map the distribution of molecular species from a tissue section without the use of tags or labels. First applied to thin tissue sections in 1997, the field of IMS has grown rapidly within the pharmaceutical and clinical fields because of its unique ability to map hundreds of compounds in tissue in a single measurement. Two general types of IMS studies have evolved: monitoring and discovery. Monitoring studies seek to visualize the distribution of known target compounds such as a dosed therapeutic and/or its metabolites. In discovery IMS studies, the collection of pixels, or spectra, from a cohort of samples are analyzed to identify which molecular signals are likely to be good predictors/indicators of biological activity. Of particular interest is that when ion images are combined with histology it is often found that cells that present similar histopathology express very different molecular, or proteomic, profiles. The early years of IMS saw a few select innovators publish seminal papers that demonstrated its potential role in affecting clinical outcomes. It can be argued that the explosive growth of IMS applications in recent years (presently >200 publications/year) is due to the availability of commercial instrumentation and software that builds upon the work of early innovators to move the technology beyond traditional mass spectrometry labs. IMS studies have examined analytes ranging from drug/metabolites to lipids to carbohydrates to peptides and large proteins from a wide variety of clinical, animal-model and plant samples.
In less than ten years Bruker Daltonics has become the market leader for IMS providing instrumentation and software tools for all aspects of the IMS workflow. While any commercial MALDI system can be configured to produce ion images, our work alongside our collaboration partners has shown us that the greater challenges for a translating image data into knowledge lies within the pre- and post-acquisition phases of experimental design and data analysis. In this seminar we will highlight some of the experiences that have driven development of our IMS products and continue to expand our understanding of the challenges and potential of IMS. Specific topics will include: expanding the view of pharmaceutical target monitoring and discovering clinical biomarkers through molecular histology.
Dale Shannon Cornett received his Ph.D. in analytical chemistry from the University of Georgia in 1993, working under the mentorship of Jon Amster. Following a post-doc with Terry Lee at City of Hope, Shannon joined Bruker and spent 8 years in the mass spectrometry division as Applications Scientist, R&D Manager and Product Manager. In 2002, he moved to the Mass Spectrometry Research Facility at Vanderbilt University as Research Assistant Professor to work with Professor Richard Caprioli to develop new tools and methodologies for the then-emerging field of imaging mass spectrometry. Shannon rejoined Bruker Daltonics in 2009 as a Product Specialist supporting the MALDI imaging and proteomics. He currently is Manager of Applications Development for the Americas and also holds an adjunct appointment in biochemistry at Vanderbilt. Dr. Cornett has authored 25 publications in MALDI instrumentation and applications.